<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">278</article-id><article-id pub-id-type="doi">10.36691/RJA278</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">DIAGNOSIS OF DELAYED DRUG ALLERGIC REACTIONS</article-title><trans-title-group xml:lang="ru"><trans-title>ДИАГНОСТИКА ЛЕКАРСТВЕННОЙ АЛЛЕРГИИ, ПРОТЕКАЮЩЕЙ ПО ЗАМЕДЛЕННОМУ ТИПУ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Romanova</surname><given-names>T S</given-names></name><name xml:lang="ru"><surname>Романова</surname><given-names>Татьяна Сергеевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач аллерголог-иммунолог, научный сотрудник отделения иммунопатологии.</p></bio><email>tsromanova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Myasnikova</surname><given-names>T N</given-names></name><name xml:lang="ru"><surname>Мясникова</surname><given-names>Татьяна Николаевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>старший научный сотрудник отделения иммунопатологии, кандидат медицинских наук.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khludova</surname><given-names>L V</given-names></name><name xml:lang="ru"><surname>Хлудова</surname><given-names>Людмила Геннадьевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант отделения иммунопатологии</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Smirnov</surname><given-names>V G</given-names></name><name xml:lang="ru"><surname>Смирнов</surname><given-names>Валерий Валерьевич</given-names></name></name-alternatives><bio xml:lang="ru"><p>заведующий лабораторией № 73, кандидат фармакологических наук.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Latysheva</surname><given-names>T V</given-names></name><name xml:lang="ru"><surname>Латышева</surname><given-names>Татьяна Васильевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>руководитель отделений иммунопатологии и интенсивной терапии, анестезиолог-реаниматолог, Заслуженный врач России, доктор медицинских наук, профессор</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">NRC Institute of Immunology FMBA of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «ГНЦ Институт иммунологии» ФМБА России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-12-14" publication-format="electronic"><day>14</day><month>12</month><year>2017</year></pub-date><volume>14</volume><issue>6</issue><issue-title xml:lang="en">NO6 (2017)</issue-title><issue-title xml:lang="ru">№6 (2017)</issue-title><fpage>7</fpage><lpage>20</lpage><history><date date-type="received" iso-8601-date="2020-03-10"><day>10</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, Фармарус Принт Медиа</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2019-12-15"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/278">https://rusalljournal.ru/raj/article/view/278</self-uri><abstract xml:lang="en"><p>Mechanisms of delayed druginduced allergies (DDIA), individual features of the immune response to the drug, influence of various cofactors (concomitant pathology, viral infection, insolation, etc.) create difficulties in diagnostics of drug allergy (DA). Identification and elimination of a causative drug allows to prevent the development of severe allergic reactions. Verification of DA diagnosis during the survey allows to avoid the unreasonable lifelong ban on application of certain drug, which often leads to decreasing of treatment efficiency and increasing its cost. In vitro diagnostic tests are safe, but laborious and expensive. This article will provide the review of literature, reflecting a modern view on the diagnosis of DDIA.</p></abstract><trans-abstract xml:lang="ru"><p>Сложность механизмов развития лекарственной аллергии замедленного типа (ЛАЗТ), индивидуальные особенности иммунного ответа на лекарственный препарат (ЛП), влияние различных кофакторов (сопутствующая патология, вирусная инфекция, инсоляция и т. п.) создают трудности при разработке диагностических тестов. Необходимо не только правильно поставить диагноз, но и выявить причиннозначимый ЛП, исключение которого позволяет профилактировать развитие повторных аллергических реакций, которые, как правило, протекают тяжелее. Исключение диагноза лекарственной аллергии (ЛА) в ходе обследования позволяет избежать необоснованных пожизненных запретов на применение тех или иных ЛП, которые зачастую приводят к снижению эффективности лечения и увеличению его стоимости. Методы диагностики in vitro безопасные, но трудоемкие и дорогостоящие. В обзоре отражен современный взгляд на диагностику лекарственной аллергии, протекающей по замедленному типу.</p></trans-abstract><kwd-group xml:lang="en"><kwd>delayed drug-induced allergic reactions</kwd><kwd>in vitro tests</kwd><kwd>lymphocyte transformation test</kwd><kwd>cytokines</kwd><kwd>CD69 expression</kwd><kwd>cytotoxic reactions</kwd><kwd>major histocompatibility complex</kwd><kwd>in vivo tests</kwd><kwd>skin testing</kwd><kwd>graded challenge test</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>лекарственная аллергия замедленного типа</kwd><kwd>методы диагностики in vitro</kwd><kwd>тест трансформации лимфоцитов</kwd><kwd>цитокины</kwd><kwd>экспрессия CD69</kwd><kwd>цитотоксические реакции</kwd><kwd>главный комплекс гистосовместимости</kwd><kwd>методы диагностики in vivo</kwd><kwd>кожное тестирование</kwd><kwd>провокационный дозируемый тест</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol. 2003; 2(3): 278-299.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Mayorga C, Sanz ML, Gamboa P, Garcia-Aviles MC, Fernande J, Torres MJ, on behalf of the Spanish Society of Allergy and Clinical Immunology (SEAIC) Immunology and Drug Allergy Committee, In Vitro Methods for Diagnosing Non-immediate Hypersensitivity Reactions to Drugs. J Investig Allergol Clin Immunol. 2013; 23(4): 213-225.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Thong BY, Mirakian R, Castells M, Pichler WJ, Romano A, Bonadonna P, Diana D, Kowalski M, Yanez A, Lleonart R, Sanchez-Borges M, Demoly P. A world allergy organization international survey on diagnostic procedures and therapies in drug allergy/hypersensitivity. World Allergy Organ J. 2011; 4(12): 257-270. DOI: 10.1097/W0X.0b013e31823dc02c.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Nyfeler B, Pichler WJ. The lymphocyte transformation test in for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy. 1997; 27: 175-181. DOI: 10.1111/j.1365-2222.1997.tb00690.x.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Pichler WJ, Tilch J. The lymphocyte transformation test in for the diagnosis of drug hypersensitivity. Allergy. 2004; 59(8): 809-820. DOI: 10.1111/j.1398-9995.2004.00547.x.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G. In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Mol Diagn Ther. 2009; 13(5): 313-30. DOI: 10.1007/bf03256336.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007; 62(12): 1439-1444. DOI: 10.1111/j.1398-9995.2007.01553.x.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Schnyder B, Pichler WJ. Skin and laboratory tests in amoxicillin and penicillin-induced morbilliform skin eruption. Clin Exp Allergy. 2000; 30(4): 590-595. DOI: 10.1046/j.1365-2222.2000.00787.x.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Rodriguez-Pena R, Lopez S, Mayorga C, Antunez C, Fernandez TD, Torres MJ, Blanca M. Potential involvement of dendritic. cells in delayed-type hypersensitivity reactions to betalactams. J Allergy Clin Immunol. 2006; 118(4): 949-56. DOI: 10.1016/j.jaci.2006.07.013.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>El-Ghaiesh S, Sanderson JP, Farrell J, Lavergne SN, Syn WK, Pirmohamed M, Park BK, Naisbitt DJ. Characterization of drug-specific lymphocyte responses in a patient with drug-induced liver injury. J Allergy Clin Immunol. 2011; 128(3): 680-683. DOI: 10.1016/j.jaci.2011.04.031.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Berger D, Pichler W, Savic S, Schoenenberger R, Borer H. Fever, pneumonia and eosinophilia. Praxis. 2007; 96(40): 1543-1547. DOI: 10.1024/1661-8157.96.40.1543.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Matsuno O, Okubo T, Hiroshige S, Takenaka R, Ono E, Ueno T, Nureki S, Ando M, Miyazaki E, Kumamoto T. Drug induced lymphocyte stimulation test is not useful for the diagnosis of drug-induced pneumonia. Tohoku J Exp Med. 2007; 212(1): 49-53. DOI: 10.1620/tjem.212.49.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Ono E, Miyazaki E, Matsuno O, Nureki S, Okubo T, Ando M, Kumamoto T. Minocycline-Induced Acute Eosinophilic Pneumonia: Controversial Results of Lymphocyte Stimulation Test and Re-challenge Test. Intern Med. 2007; 46(9): 593-595. DOI: 10.2169/internalmedicine.46.6235.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012; 13(1): 39. DOI: 10.1186/1465-9921-13-39.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Spanou Z, Keller M, Britschgi M, Yawalkar N, Fehr T, Neuweiler J, Gugger M, Mohaupt M, Pichler WJ. Involvement of drugspecific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol. 2006; 17(10): 2919-2927. DOI: 10.1681/asn.2006050418.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Beeler A, Pichler WJ. In vitro Tests of T-Cell-Mediated Drug Hypersensitivity. Drug Hypersensensivity. Basel, Karger. 2007: 380-390. DOI: 10.1159/000104215.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Beeler A, Zaccaria L, Kawabata T, Gerber BO, Pichler WJ. CD69 upregulation on T-cells as an in vitro marker for de-layed-type drug hypersensitivity. Allergy. 2008; 63(2): 181-188. DOI: 10.1111/j.1398-9995.2007.01516.x.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Porebski G, Gschwend-Zawodniak A, Pichler WJ. In vitro diagnosis of T-cell-mediated drug allergy. Clin Exp Allergy. 2011; 41(4): 461-470. DOI: 10.1111/j.1365-2222.2011.03701.x.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Halevy S, Cohen AD, Grossman N. Clinical implications of in vitro drug-induced interferon gamma release from peripheral blood lymhpocytes in cutaneous adverse drug reaction. J Am Acad Dermatol. 2005; 52(2): 254-261. DOI: 10.1016/j.jaad.2004.05.006.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Naisbitt DJ, Farrell J, Wong G, Depta JH, Dodd CC et al. Characterizations of drug-specific T-cell in lamotrigine hypersensitivity. J Allergy Clin Immunol. 2003; 111(6): 1393-1403. DOI: 10.1067/mai.2003.1507.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Hari Y, Urwyler A, Hurni M, Yawalkar N, Dahinden C et al. Distinkt serum cytokine levels in drug and measles-induced exantemа. Int Arch Allergy Immunol. 1999; 120(3): 225-229. DOI: 10.1159/000024271.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Pichler WJ, Zanni M, von Greyerz S, Schnyder B, Mau-ri-Hellweg D, Wendland T. High IL-5 production by human drug-specific T-cell clones. Int Arch Allergy Immunol. 1997; 113(1-3): 177-180. DOI: 10.1159/000237539.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Sachs B, Erdmann S, Al-Masauodi T, Merk HF. In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. Br J Dermatol. 2001; 144(2): 316-320. DOI: 10.1046/j.1365-2133.2001.04021.x.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Yawalkar N, Shrikhande M, Hari Y, Nievergelt H, Braathen LR, Pichler WJ. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruphion. J Allergy Clin Immunol. 2000; 106(6): 1171-1176. DOI: 10.1067/mai.2000.110922.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Khalil G, EL-Sabban M., AL-Ghadban S et al. Cytokine expression profile of sensitized human T-lymphocytes following in vitro stimulation with amoxicillin. Eur Cytokin Netw. 2008; 19(3): 131-141.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Lochmatter P, Beeler A, Kawabata TT, Gerber BO, Pichler WJ. Drug-specific in vitro relese of IL-2, IL-5, IL-13 and IFN-y in patients with delayed-type drug hypersensitivity. Allergy. 2009; 64(9): 1269-1278. DOI: 10.1111/j.1398-9995.2009.01985.x.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Britschgi M, Pichler WJ. Acute generalized exantematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T-cells. Curr Opin Allergy ClinImmunol. 2002; 2(4): 325-331. DOI: 10.1097/00130832-20020800000006.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Yawalkar N, Egli Y, Hari Y, Nievergelt H, Braathen LR, Pichler WJ. Infiltration of cytotoxic T-cells in drug-induced cutaneous eruptions. Clin Exp Allergy. 2000; 30(6): 847-855. DOI: 10.1046/j.1365-2222.2000.00847.x.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P et al. Toхic epidermal necrolysis: effector cells are drug-specific cytotoxic T-cells. J Allergy Clin Immunol. 2004; 114(5): 1209-1215. DOI: 10.1016/j.jaci.2004.07.047.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Chung WH, Hung SI, Yang JY, Su SC, Huang SP et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Jonson syndrome and toхic epidermal necrolysis. Nat Med. 2008; 14(12): 1343-1350. DOI: 10.1038/nm.1884.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Schmid S, Kuechler PC, Britshgi M, Steiner UC, Yawalkar N et al. Acute generalized exantematous pustulosis: role of cytotoxic T-cells in pustule formation. Am J Pathol. 2002; 161(6): 2079-2086. DOI: 10.1016/S0002-9440(10)64486-0.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Hari Y, Frutig-Schnyder K, Hurni M, Yawalkar N, Zanny MP et al. T-cell involvement in cutaneous drug eruptions. Clin Exp Allergy. 2001; 31(9): 1398-1408. DOI: 10.1046/j.1365-2222.2001.01164.x.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Viard I, Wehrli P, Bullani R, Schneider P, Holler N et al. Inhibition of toxic epidermal necrolysis by blocade of CD95 with human intravenous immunoglobulin. Science. 1998; 282(5388): 490-493. DOI: 10.1126/science.282.5388.490.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Porebski G, Gschwend-Zawodniak A, Pichler WJ. In vitro diagnosis of T-cell-mediated drug allergy. Clin Exp Alergy. 2011; 41(4): 461-470. DOI: 10.1111/j.1365-2222.2011.03701.x.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Zawodniak A, Lochmatter P, Yerly D, Kawabata T, Lerch M, Yawalkar N, Pichler WJ. In vitro detection of cytotoxic T- and NK-cells in peripheral blood of patients with various drug-induced skin diseases. Allergy. 2010; 65(3): 376-384. DOI: 10.1111/j.1398-9995.2009.02180.x.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Porebski G, Czarnobilska E, Bosak M. Cytotoxic-based assays in delayed drug hypersensitivity reactons induced by antiepileptic drugs. Pol Arch Med Wewn. 2015; 125(11)823-834. DOI: 10.20452/pamw.3160.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002; (359): 727-732. DOI: 10.1016/S0140-6736(02)07873-X.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genomics. 2009; (19): 704-709. DOI: 10.1097/fpc.0b013e328330a3b8.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Hung SI, Chung WH, Liou LB, Chu СС, Lin M et al. HLA-B*5801 allele as genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005; 102(11): 4134-4139. DOI: 10.1073/pnas.0409500102.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tochkin M et al. HLA-B locus in Japanese patients treated with anti-epileptic and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics J. 2008; 9(11): 1617-1622. DOI: 10.2217/14622416.9.11.1617.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Lonjou C, Thomas L, Borot N, Ledger N, Toma C et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J. 2006; 6(4): 265-268. DOI: 10.1038/sj.tpj.6500356.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004; 428(6982): 486. DOI: 10.1038/428486a.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, Ng MHL. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007; 48(5): 1015-1018. DOI: 10.1111/j.1528-1167.2007.01022.x.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T Tongkobpetch S. Carbamazepin and phenytoin induced Stevens-Johnson syndrome is associated with the HLA-B*1502 allele in a Thai population. Epilepsia, 2008; (49): 2087-2091. DOI: 10.1111/j.1528-1167.2008.01719.x.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Metha TY, Prajapati LM, Mittal B, Joshi C, Sheth J et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol. 2009; 75(6): 579-582. DOI: 10.4103/0378-6323.57718.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>MCCormak M, Afirevic A, Bourgeois S, Farrell JJ, Deloukas P, Delanty N et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011; (64): 1134-1143. DOI: 10.3410/f.9454964.10254054.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Barbaud A, Reichert-Penetrat S, Trechot P, Jacquin-Petit, Ehlinger et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol. 1998; 139(1): 49-58. DOI: 10.1046/j.1365-2133.1998.02313.x.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Bruynzeel DP, Maibach HI. Pach testing in systemic drug eruptions. Clin Dermatol. 1997; 15(4): 479-484. DOI: 10.1016/s0738-081x(97)00007-2.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Klein CE, Trautmann A, Zillikens D, Brocker EB. Patch testing in an unusual case of toxic epidermal necrolysis. Contact Dermatitis. 1996; 35(3): 175-176. DOI: 10.1111/j.1600-0536.1996.tb02339.x.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Machet L, Vaillant L, Dardaine V, Lorette G. Patch testing with clobazam: relapse of generalized drug eruption. Contact Dermatitis. 1992; 26(5): 347-348. DOI: 10.1111/j.1600-0536.1992.tb00132.x.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, Khan DA, Lang Dm, Park HS, Pichler W, Sanchez-Borges M, Shiohara N, Thong YH. International consensus on drug allergy. Allergy. 2014; 69(4): 420-437. DOI: 10.1111/all.12350.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002; 57(1): 45-51. DOI: 10.1046/j.0105-4538.2001.00001.x-i8.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Johansen JD, Aalto-Korte K, Agner T, Andersen KE, Bircher A et al. European Society of Contact Dermatitis guideline for diagnostic patch testing-recommendations on best practice. Contact Dermatitis. 2015; 73(4): 195-221. DOI: 10.1111/cod.12432.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Harr T. Diagnostic approach to drug allergy. In: French L.E. Adverse Cutaneous Drug Eruptions. Basel, Karger. 2012; (97): 47-60. DOI: 10.1159/000335615.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Клиническая аллергология: Руководство для практических врачей. Под ред. Р.М. Хаитова. М.: Медпресс-информ, 2002: 623. [Clinical allergology: The management for practical doctors. Khaitov RM. Moscow: Medpress-inform, 2002: 623 (In Russ.)].</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Romano A, Viola M, Mondino C, Pettinato R, Di Fonso M, Papa G et al. Diagnosing nonimmediate reactions to pencillinis by in vivo tests. In Arch Allergy Immunol. 2002; 129(2): 169-174. DOI: 10.1159/000065876.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin test to prove drug hypersensitivity. Br J Dermatol. 2005; 152(5): 968-974. DOI: 10.1111/j.1365-2133.2005.06429.x.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Phillips EJ, Sullivan JR, Knowles SR, Shear NH. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS. 2002; 16(16): 2223-2225. DOI: 10.1097/00002030-200211080-00017.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Phadial A, Antunez C, Blanca-Lopez N, Fernandez TD, Cornejo-Garcia JA, Mayorga C et al. Non-immediate reactions to betalactams: diagnostic value of skin testing and drug provocation test. Clin Exp Allergy. 2008; 38(5): 822-828. DOI: 10.1111/j.1365-2222.2008.02961.x.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Terrados S, Blanca M, Garcia J, Vega JM, Torres MJ et al. Non-immediate reactions to betalactams: prevalence and role ofthe different penicillins. Allergy. 1995; 50(7): 563-567. DOI: 10.1111/j.1398-9995.1995.tb01200.x.</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Haan P, Bruynzeel DP, Van Ketel WG. Onset of penicillin rashes: relation between type of penicillin administered and type of immune reactivity. Allergy. 1986; 41(1): 75-78. DOI: 10.1111/j.1398-9995.1986.tb00279.x.</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Romano A, Blanca M., Torres MJ, Bircher A, Aberer W et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy. 2004; 59(11): 1153-1160. DOI: 10.1111/j.1398-9995.2004.00678.x.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Torres MJ, Sánchez-Sabaté E, Alvarez J, Mayorga C, Fernandez J, Padial A, Cornejo-Garcia JA, Bellôn T, Blanca M. Skin test evaluation in nonimmediate allergic reactions to penicillins. Allergy. 2004; 59(2): 219-224. DOI: 10.1046/j.1398-9995.2003.00308.x.</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Vezir E, Dibek Misirliogu E, Civelek E, Capanoglu M, Gu-venir H et al. Direct oral provocation test in non-immediate mild cutaneous reactions related to beta-lactam antibiotics. Pediatric Allergy and Immunology. 2016; 27(1): 50-54. DOI: 10.1111/pai.12493.</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Romano A, Quaratino D, Papa G, Di Fonso M, Venuti A. Aminopenicillin allergy. Arch Dis Child. 1997; 76(6): 513-517. DOI: 10.1136/adc.76.6.513.</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Blanca-Lopez N, Zapatero L, Alonso E, Torres J, Fuentes V, Martinez-Molero I, Blanca M. Skin testing and drug provocation in nonimmediate reactions to aminopenicillins in children. Allergy. 2009; 64(2): 229-233. DOI: 10.1111/j.1398-9995.2008.01903.x.</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Mendelson LM, Ressler C, Rosen JP, Selcow JE. Routine elective penicillin allergy skin testing in children and adolescents: study of sensitization. J Allergy Clin Immunol. 1984; 73(1): 76-DOI: 10.1016/0091-6749(84)90487-1.</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Moral L, Garde J, Toral T, Fuentes MJ, Marco N. Short protocol for the study of paediatric patients with suspected betalactam antibiotics hypersensitivity and low risk criteria. Allergol Immunopathol. 2011; 39(6): 337-341. DOI: doi. org/10.1016/j.aller.2010.10.002.</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Barbaud A., Goncalo M., Bruynzeel D. et al. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis. 2001; 45(6): 321-328. DOI: 10.1034/j.1600-0536.2001.450601.x.</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Wolkenstein P, Chosidow O, Flechet ML, Bircher A. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis. 1996; 35(4): 234-236. DOI: 10.1111/ j.1600-0536.1996.tb02364.x.</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Macias E, Ruiz A, Moreno E, Laffond E, Davila I, Lo-rente F. Usefulness of interdermal test and patch test in the diagnosis of nonimmediate reactions to metamizol. Allergy. 2007; 62(12): 1462-1464. DOI: 10.1111/j.1398-9995.2007.01487.x.</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Vernassiere C, Trechot P, Commun N, Schmutz JL, Barbaud A. Low negative predictive value of skin tests in investigating delayed reactions to radio-contrast media. Contact Dermatitis. 2004; 50(6): 359-366. DOI: 10.1111/j.0105-1873.2004.00367.x.</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Brockow K, Romano A, Aberer W, Bircher AJ, Barbaud A et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy. 2009; 64(2): 234-241. DOI: 10.1111/j.1398-9995.2008.01832.x.</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Лебедева НВ. Особенности диагностики и тактики ведения пациентов, перенесших реакции гиперчувствительности после введения йодсодержащих рентгеноконтрастных средств. Диссертация на соискание ученой степени кандидата мед. наук. М., 2013, 142 с. [Lebedeva N.V. Features of diagnostics and tactics of maintaining the patients who transferred reactions of a hypersensitivity after introduction of iodinated contrast tools. Dissertation for the degree of Candidate of Medical Sciences. M., 2013; 142 (In Russ.)].</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Aberer W, Birchera A, Romano A, Blanca M, Campi P et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy. 2003; 58(9): 854-863. DOI: 10.1034/j.1398-9995.2003.00279.x.</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Gleckman RA, Borrego F. Adverse reactions to antibiotics. Postgrad Med. 1997; 101(4): 97-108. DOI: 0.3810/pgm.1997.04.198.</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Casadevall J, Ventura PJ, Mullol J, Picado C. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by accoustic rhinometry. Thorax. 2000; 55(11): 921-924. DOI: 10.1136/thorax.55.11.921.</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Nizankowska E, Bestynska-Krypel A, Cmiel A, Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J. 2000; 15(5): 863-869. DOI: 10.1034/j.1399-3003.2000.15e09.x.</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Hannuksela M, Salu H. The repeated open application test (ROAT). Contact Dermatitis. 1986; 14(4): 221-227. DOI: 10.1111/j.1600-0536.1986.tb01229.x.</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Lopez Serrano MC, Caballero MT, Barranco P, Martinez-Alzamora F. Booster responses in the study of allergic reactions to beta-lactam antibiotics. J Invest Allergol Clin Immunol. 1996; 6(1): 30-35.</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>Romano A, Gaeta F, Valluzzi RL, Caruso C, Alonzi C, Viola M et al. Diagnosing nonimmediate reactions to cephalosporins. J Allergy Clin Immunol. 2012; 129(4): 1166-1169. DOI: 10.1016/j.jaci.2011.12.995.</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>Kauppinen K, Stubb S. Fixed eruptions - causative drugs and challenge tests. Br J Dermatol. 1985; 112(5): 575-578. DOI: 10.1111/j.1365-2133.1985.tb15266.x.</mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation>Blanca M, Fernandez J, Miranda A, Terrados S, Torres MJ et al. Cross-reactivity between penicillins and cephalosporins; clinical and immunologic studies. J Allergy Clin Immunol. 1989; 83(2): 381-385. DOI: 10.1016/0091-6749(89)90122-x.</mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation>Romano A, Di Fonso M, Papa G, Pietrantonio F, Federico F et al. Evaluation of adverse cutaneous reactions to aminopen-icillins with emphasis on those manifested by maculopapular rashes. Allergy. 1995; 50(2): 113-118. DOI: 10.1111/j.1398-9995.1995.tb05066.x.</mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation>Torres MJ, Mayorga C, Leyva L, Guzman AE, Cornejo-Garcia JA, Juarez C, Blanca M. Controlled administration of penicillin to patients with a positive history but negative skin and specific serum IgE tests. Clin Exp Allergy. 2002; 32(2): 270-276. DOI: 10.1046/j.1365-2222.2002.01296.x.</mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation>Romano A, Quaratino D, Di Fonso M, Papa G, Venuti A, Gasbarrini G. A diagnostic protocol for evaluationg nonimme-diate reactions to aminopenicillins. J Allergy Clin Immunol. 1999; 103(6): 1186-1190. DOI: 10.1016/s0091-6749(99)70197-1.</mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation>Hein UR, Chantraine-Hess S, Worm M, Zuberbier T, Henz BM. Evaluation of systemic provocation tests in patients with suspected allergic and pseudoallergic drug reactions. Acta Derm Venereol. 1999; 79(2): 139-142. DOI: 10.1080/000155599750011372.</mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation>Ring L, Galosi A, Przybilla B. Reverse placebo provocation in the diagnosis of anaphylactoid reactions to local anesthetics. J Allergy Clin Immunol. 1986; 77: 225. DOI: 10.1016/0030-4220(93)90427-6.</mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation>Moneret-Vautrin DA, Gueant JL, Kamel L, Laxenaire MC, El Kholty S, Nicolas JP. Anaphylaxis to muscle relaxants: cross-sensitivity studied by radioimmunoassays compared to intradermal tests in 34 cases. J Allergy Clin Immunol. 1988; 82(5): 745-752.</mixed-citation></ref></ref-list></back></article>
